Vienna, United States
Cel-Sci is a biotechnology company dedicated to researching and developing treatments for cancer, autoimmune, and infectious diseases. The company's flagship product, Multikine, aims to boost the patient's immune system to target tumors while it is still intact and before conventional therapies. In a completed Phase 3 study, Multikine showed statistically significant survival rates in locally advanced primary head and neck cancer patients with specific characteristics. The product has also received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck.
Founded in 1983 and headquartered in the United States, Cel-Sci recently secured a $10.85 million investment in post-IPO equity. The investment, made by an undisclosed investor, signifies a vote of confidence in the company's innovative approach to cancer treatment. Cel-Sci's unique strategy of administering immunotherapy before conventional treatments sets it apart in the biotechnology and healthcare industries, potentially offering a promising solution to unmet medical needs.
